CBD nutraceuticals market seen doubling by 2033

By AI, Created 5:36 AM UTC, June 01, 2026, /AGP/ – The global CBD nutraceuticals market is projected to rise from $11.7 billion in 2026 to $26.3 billion by 2033, driven by demand for plant-based wellness products, wider legalization, and growing use in supplements. Regulators still pose a major hurdle as capsules and softgels emerge as the fastest-growing format and North America holds the largest share.

Why it matters: - The CBD nutraceuticals market is moving from niche wellness to a broader consumer category as demand for natural, plant-based products accelerates. - The market’s projected rise to $26.3 billion by 2033 points to sustained growth for hemp-derived supplements, formats, and distribution channels. - Regulatory clarity will shape how quickly manufacturers can scale across regions.

What happened: - Industry estimates project the global CBD nutraceuticals market will grow from $11.7 billion in 2026 to $26.3 billion by 2033. - The forecast implies a 12.3% compound annual growth rate over the period. - The market is being lifted by greater awareness of CBD’s health benefits, expanding legalization frameworks, and rising adoption of wellness supplements. - CBD nutraceuticals are being used in products tied to pain management, sleep improvement, stress reduction, and general well-being. - The press release was issued June 1, 2026. - A free sample report is available here.

The details: - Consumer preference for natural and organic health products is a major growth driver. - CBD products align with clean-label and plant-based purchasing trends. - Rising chronic pain, anxiety, stress-related disorders, and sleep disturbances are pushing consumers toward non-invasive wellness options. - CBD tinctures held the largest product share in 2025 at 55.5% of global revenue. - Tinctures remain popular because of faster absorption and higher bioavailability than many other formats. - Capsules and softgels are the fastest-growing product category. - Capsules and softgels appeal to consumers seeking precise dosing, convenience, and familiar supplement formats. - Pain management remains the leading application segment. - North America held 69.7% of global market share in 2025. - The United States is the largest national market. - Canada is growing quickly because of its fully legalized cannabis framework. - Europe is expanding steadily, led by Germany and with the United Kingdom among the fastest-growing markets. - Asia-Pacific growth is being supported by rising disposable incomes, greater consumer awareness, and interest in traditional plant-based therapies. - China remains a major producer of hemp-derived ingredients. - India is seeing higher CBD adoption in wellness and Ayurvedic health segments.

Between the lines: - Regulatory fragmentation is the biggest constraint on near-term growth. - Rules differ by country and region on product classification, dosage limits, labeling, and marketing. - Those differences raise compliance costs and can delay launches. - The fastest opportunities are likely in standardized formats that reduce consumer friction, such as capsules and softgels. - The market still tilts toward tinctures, but convenience-driven products could erode that lead over time.

What’s next: - Manufacturers are likely to keep investing in product innovation and delivery technologies. - Industry participants are pushing for clearer, more consistent regulatory pathways. - Better regulation could lower launch barriers and unlock more cross-border growth. - The competitive set is expected to stay focused on quality assurance, compliance, and portfolio expansion.

The bottom line: - CBD nutraceuticals are set for strong global growth, but regulatory consistency will determine how much of that demand turns into revenue.